Their increased expression has been regarded as an indicator in the treatment of ovarian cancer: increased PMCA1 expression was found in ovarian cancer cells resistant to cisplatin, whereas its expression was lower in cells sensitive to this drug [158,159]. Here, ATP2B1 is linked to ovarian carcinoma.